| Literature DB >> 32624659 |
Jin Lee1, Yong Eun Park1, Joon Hyuk Choi1, Nae-Yun Heo1, Jongha Park1, Seung Ha Park1, Young Soo Moon1, Kyung Han Nam2, Tae Oh Kim1.
Abstract
BACKGROUND: Modified endoscopic mucosal resection (EMR) is considered a treatment option for rectal neuroendocrine tumors (NETs) <10 mm in diameter. In this study, we evaluated the clinical outcomes of cap-assisted EMR (EMR-C) and EMR with a ligating device (EMR-L).Entities:
Keywords: Rectal neuroendocrine tumor; cap-assisted; endoscopic mucosal resection-ligating device
Year: 2020 PMID: 32624659 PMCID: PMC7315720 DOI: 10.20524/aog.2020.0485
Source DB: PubMed Journal: Ann Gastroenterol ISSN: 1108-7471
Figure 1Cap-assisted endoscopic mucosal resection. (A) A yellowish tumor was detected; (B) adequate lift after submucosal injection; (C) endoscopic suctioning of the tumor into the cap followed by closure of the snare; (D) complete resection with no signs of perforation or residual tissue
Figure 2Endoscopic mucosal resection with a ligating device. (A) Aspiration of a tumor into the ligating device; (B) deployed elastic band; (C) snare resection performed below the band; (D) complete resection with no signs of perforation or residual tissue
Baseline characteristics of patients and tumors
Clinical outcomes of EMR-C and EMR-L
Figure 3Histopathologic images of a rectal neuroendocrine tumor with both vertical and lateral margin involvements. Vertical (black arrow) and lateral (gray arrow) margin involvements are noted. (A) H&E stain, ×1.5; (B) ×100
Risk factors for positive resection margin of rectal neuroendocrine tumor